

AN 1997-044618 [05] WPIDS  
 CR 1998-448966 [39]  
 DNC C1997-014283  
 TI Antidiabetic compsn. comprises insulin sensitivity enhancer - in combination with e.g. alpha-glucosidase inhibitors, aldose reductase inhibitors, bi guanide(s), statin cpds. and squalene synthesis inhibitors.  
 DC B02 B03  
 IN IKEDA, H; ODAKA, H; SOHDA, T  
 PA (TAKE) TAKEDA CHEM IND LTD; (TAKE) TAKEDA YAKUHHIN KOGYO KK  
 CYC 29

PI EP----749751 A2 19961227 (199705)\* EN 16p  
 R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE  
 CZ---9601811 A3 19970115 (199709)  
 NO---9602606 A 19961223 (199709)  
 AU---9656034 A 19970109 (199710)  
 SK---9600794 A3 19970108 (199711)  
 CA---2179584 A 19961221 (199716)  
 JP--09067271 A 19970311 (199720) 14p <--  
 EP----749751 A3 19970416 (199729)  
 KR--97000233 A 19970121 (199801)  
 HU---9601698 A2 19970528 (199803)  
 ZA---9605190 A 19980225 (199813) 43p  
 MX---9602399 A1 19970201 (199818)  
 BR---1100755 A3 19980505 (199825)  
 JP--10167986 A 19980623 (199835) 16p  
 US---5952356 A 19990914 (199944)  
 ADT EP----749751 A2 1996EP-0304570 19960620; CZ---9601811 A3 1996CZ-0001811 19960619; NO---9602606 A 1996NO-0002606 19960619; AU---9656034 A 1996AU-0056034 19960618; SK---9600794 A3 1996SK-0000794 19960618; CA---2179584 A 1996CA-2179584 19960620; JP--09067271 A 1996JP-0156725 19960618; EP----749751 A3 1996EP-0304570 19960620; KR--97000233 A 1996KR-0022615 19960620; HU---9601698 A2 1996HU-0001698 19960620; ZA---9605190 A 1996ZA-0005190 19960619; MX---9602399 A1 1996MX-0002399 19960619; BR---1100755 A3 1997BR-1100755 19970512; JP--10167986 A Div ex 1996JP-0156725 19960618, 1997JP-0360756 19960618; US---5952356 A 1996US-0667979 19960619  
 PRAI 1995JP-0153500 19950620  
 AN 1997-044618 [05] WPIDS  
 CR 1998-448966 [39]  
 AB EP 749751 A UPAB: 19981001

Antidiabetic compsn. comprises an insulin sensitivity enhancer in combination with at least one of: an alpha -glucosidase inhibitor, an aldose reductase inhibitor, a biguanide, a statin cpd., a squalene synthesis inhibitor, a fibrate cpd., a LDL catabolism enhancer and an angiotensin converting enzyme inhibitor. Also claimed is a compsn. comprising a cpd. of formula (II) or its salts in combination with an insulin secretion enhancer and/or an insulin prepn. R<sup>1</sup> = opt. subst. hydrocarbon or heterocyclic gp.; Y = CO, CH(OH) or NR<sub>3</sub>; R<sub>3</sub> = opt. subst. alkyl; m = 0 or 1; n = 0 or 1, 2; X = CH or N; A = a bond or 1-7C divalent aliphatic hydrocarbon gp.; Q = 0 or S; R<sub>1</sub> = H or an alkyl gp.; ring E may opt. have further 1-4 substit. opt. combined with R<sub>1</sub> to form a ring, provided that R<sub>1</sub> does not represent benzopyranyl gp. when m and n = 0; X = CH; A = represents a bond; Q = S; R<sub>1</sub>, L and M = H and ring E does not have any further substituents.

USE - Compsn. has a potent depressive effect on diabetic hyperglycaemia and is useful in the prophylaxis or treatment of diabetes. The dosage of the insulin sensitivity enhancer is 0.01-10 (pref. 0.05-10, esp. 0.05-5) mg/kg or 0.005-10 (pref. 0.01-10, esp. 0.01-1) mg/kg, 1-3 times/day.

ADVANTAGE - The compsn. does not cause adverse reactions (e.g. gastrointestinal disorders such as diarrhoea) even on long-term admin. and is effective for a large section of the diabetic population. The compsn. has a synergistic effect  
 Dwg.0/0